Progression to androgen independent (AI) is the main cause of death in prostate cancer, and the mechanism is still unclear. By reviewing the expression profiles of 26 prostate cancer samples in a holistic view, we found a group of genes differentially expressed in AI compared with androgendependent groups (P-valueo0.01, t-test). Focusing on apoptosis, proliferation, hormone and angiogenesis, we found a group of genes such as thioredoxin domain containing 5 , tumor necrosis factor receptor superfamily, member 10a , ribosomal protein S19 and Janus kinase 2 upregulated in AI prostate cancer, could play important roles in the transition from AD to AI and could be biomarkers of prognosis.
Introduction
Progression to androgen independent (AI) is the main cause of death in prostate cancer. Although significant advances have been made in identifying newer chemotherapeutic agents, AI prostate cancer remains a relatively chemoresistant tumor. 1 Although almost all patients with metastatic prostate cancer will initially respond to antiandrogen treatments, the majority will fail hormonal treatments in less than 2 years.
2 Molecular alterations such as androgen receptor mutations contribute to the progression of prostate cancer in an androgen-deprived environment, yet only about 50% of hormone refractory prostate cancer patients have identifiable mutations in the androgen receptors, suggesting that other mechanisms are involved in advanced prostate cancer cell survival. 3 Although the prostate is considered the prototype androgen-dependent (AD) gland, there is increasing evidence that estrogens also profoundly affect its growth, differentiation and maintenance. 4 In hormone refractory prostate cancer, estrogens may have a role as an alternative mitogenic pathway and as such may represent a possible target for therapeutic intervention when the tumor progresses from an AD to an AI proliferation stage. 5 Angiogenesis is essential for the growth and metastatic propagation of cancer, and increased microvessel formation is a feature of many cancers including prostate cancer where quantification of microvessel density correlates with disease stage and outcome. 6, 7, 8 The use of cDNA microarray technology enables us to study the expression of thousands of genes simultaneously from a relatively small sample of RNA. 9 In view of the complex array of genetic factors contributing to AI in prostate cancer, cDNA microarray provides a unique technological opportunity to study the genes involved in the progression to AI in prostate cancer. These analyses can help develop signature expression profiles, as well as identify new candidate genes for further investigation in AI prostate cancer. We use cDNA microarrays to compare the mRNA expressions in AI and AD prostate cancer, which share a common origin but differ in their phenotypic characteristics, particularly in differences in cell proliferation, hormone-related aspects and angiogenesis.
Materials and methods

RNA isolation
The prostate cancer samples and normal specimens used in this study were provided by The First Hospital at Peking University. Institutional approval was obtained for all specimens. Prostate from 26 patients diagnosed with prostate cancer (18 AD, eight AI) were obtained as well as normal mixed tissue from 20 voluntary donors with no history of prostate cancer were used as reference samples. Tissue samples were ground into a fine powder in a 10 cm ceramic mortar (RNase-free) and were then homogenized in TRIzol (Biostar, Shanghai, China). After centrifugation, the supernatant was separated from the organic phase and was extracted in an equal volume of chloroform. The aqueous phase was then precipitated by an equal volume of isopropanol at 41C, centrifuged to pellet the RNA and dissolved in Milli-Q H 2 O.
Construction of microarrays and probe preparations
The construction of the microarrays used in this study (14112 chip) was carried out following our previous report. 10 The 14112 microarrays consisted of 14 000 sequences representing 13 800 human UniGenes provided by United Gene Holdings (Shanghai, China). All the UniGene clones were verified by sequencing. There are 96 house-keeping genes included as positive controls. The negative controls include 16 rice UniGenes and 41 blank spots without DNA. The cDNA inserts were amplified with polymerase chain reaction (PCR) using universal primers in plasmid vector sequences and were then purified. 11 All PCR products were examined by agarose gel electrophoresis to ensure the quality and the identity of the amplified clones as expected. Then the amplified PCR products were dissolved in a buffer containing three single-strand conformation (SSC) solution. The solution with amplified PCR products was spotted onto homemade silylated slides using a Cartesian PixSys 7500 motion control robot (Cartesian Technologies, Irvine, CA, USA) fitted with ChipMaker Micro-Spotting Technology (TeleChem International, Sunnyvale, CA, USA). The glass slides were then hydrated for 2 h in 70% humidity, dried for 0.5 h at room temperature and ultraviolet crosslinked (65 mJ/cm 2 ). They were further processed at room temperature by soaking in 0.2% sodium dodecyl sulfate (SDS) for 10 min, distilled H 2 O for 10 min and 0.2% sodium borohydride for 10 min. The slides were dried again and ready for use. The fluorescent cDNA probes were prepared through reverse transcription of the isolated mRNAs and then purified as described. 10 The RNA samples from normal mixed tissue were labeled with Cy3-dUTP and those from prostate cancer patients with Cy5-dUTP.
Hybridization
The probe was dissolved in 20 ml of hybridization solution (5 Â SSC (0.75 M NaCl and 0.075 M sodium citrate), 0.4% SDS, 50% formamide). Microarrays were pre-hybridized with a hybridization solution containing 0.5 mg/ml of denatured salmon sperm DNA at 421C for 6 h. Fluorescent probe mixtures were denatured at 951C for 5 min and then applied onto the pre-hybridized chip under a cover glass. Chips were hybridized at 421C for 15-17 h. Next, the hybridized chips were each washed at 601C for 10 min in solutions of 2 Â SSC and 0.2% SDS, 0.1 Â SSC and 0.2% SDS, 0.1 Â SSC and then dried at room temperature.
Detection and analysis
The chips were scanned with a ScanArray 4000 (GSI Lumonics, Bellerica, MA, USA) at two wavelengths, 635 and 532 nm, to detect emission from both Cy5 and Cy3, respectively. The acquired images were analyzed using GenePix Pro 3.0 software. The intensities of each spot at the two wavelengths represent the quantity of Cy3-dUTP and Cy5-dUTP. Ratios of Cy5 to Cy3 were computed using the GenePix Pro 3.0 median of ratio method. Overall intensities were normalized using Lowess method. 12 All spots flagged 'Bad' or 'Not found' by GenePix software were removed from the final data. Genes were identified as differentially expressed by t-test statistics method when P-value o0.01, at 99% level of significance.
Results and discussion
Five hundred and forty-three genes were found significantly differentially expressed in AI compared with AD (P-valueo0.01). There were 329 upregulated and 214 downregulated genes. According to Gene Ontology, these genes belong to actin-binding, apoptosis, ATP binding, DNA binding, electron transport, G-proteincoupled receptor protein signaling pathway, guanosine triphosphate-binding, metabolism, nucleus, nucleic acid binding, hormone, proliferation, cell adhesion, calcium-iron binding, differentiation, signaling, cytoplasm, protein ubiquitination, integral to membrane and RNA binding, etc., as shown in Figure 1 . Using PathwayAssist, a network interaction and function of part of these differentially expressed genes were found, as shown in Figure 2 . (The software can be downloaded on the website: http://www.stratagene.com/products/ showProduct.aspx?pid ¼ 559.)
The dysregulation of polo-like kinase 1 (PLK1), a disintegrin and metalloproteinase domain 17 (ADAM17), S-phase kinase-associated protein 2 (SKP2) and annexin A2 (ANXA2) were detected in tumors in other studies by other methods. In our study, these genes were also found differentially expressed in AI compared with AD, that is, with the exception of ANXA2 being downregulated, the other three were upregulated.
PLK1, whose function is altered at different stages of mitosis through phosphorylation of Ser-137 and Thr-210, is a target of the retinoblastoma tumor suppressor pathway.
13 p53 is a critical target of PLK1, and its function is abrogated through the physical interaction with PLK1; meanwhile, PLK1 overexpression is significantly associated with p53 accumulation in colorectal cancers.
14 Cell-cycle arrest at G2/M after ionizing radiation of breast carcinoma cells may involve repression of the gene for PLK1. 15 Depletion of this enzyme induces apoptosis in cancer cells. 16 A high rate of PLK1 expression is seen in prostate cancer; PLK1 may thus be involved in prostate cancer tumorigenesis and progression . 17 Our results showed that PLK1 was upregulated in AI compared with AD, which suggested that overexpression of PLK1 might be of pathogenic, prognostic and proliferative importance.
ADAM17, a disintegrin and metalloproteinase domain 17 (tumor necrosis factor, alpha, converting enzyme) and overexpressed in AI compared with AD, is a member of the ADAM protein family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biologic processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development and neurogenesis. Data show that activation of ADAM17 results in discrete cellular responses, whereas G-protein-coupled receptor agonists promote activation of the Ras/mitogen-activated protein kinase Androgen-independent prostate cancer Q Wei et al Figure 1 Functional categories of representative genes differentially expressed in AI compared with AD. Expression data were centralized by the average ratio of each gene. Ratios are color-coded as indicated by the color index bar.
Androgen-independent prostate cancer Q Wei et al pathway and cell proliferation via the epidermal growth factor receptor. 18 Another report says that ADAM17 is required for epidermal growth factor receptor activation in vivo and for the development of tumors in nude mice, indicating a crucial role of ADAM17 in tumorigenesis. 19 Lower mRNA expression of ADAM17 mRNA in solitary large-cell hepatocellular carcinoma may be associated with the better molecular pathological features.
20
ADAM17 and tissue inhibitor of metalloproteinase 3 might play an important role in the pathogenesis of AI prostate cancer.
21
SKP2 plays an oncogenic role in lung cancer, and SKP2 silencing may be useful in the treatment of lung cancer and oral squamous cell carcinoma. 22, 23 Overexpression of SKP2 is associated with colorectal carcinogenesis and late metastasis to lymph nodes, whereas relative reduction of SKP2 is correlated with local invasion of primary carcinoma.
24 SKP2 overexpression is also associated with ovarian adenocarcinoma. 25 Particularly, SKP2 has a predominant role in the downregulation of p27 in S phase and interacts with S-phase kinase-associated protein 1 (SKP1 or p19) by estrogens in breast cancer cells, and it is a major determinant of p27 levels in prostate cancer cells. 26 Our result showed that overexpression of SKP2 may be one of the mechanisms that allow AI prostate cancer cells to escape growth control mediated by p27.
ANXA2 showed downregulation in AI group compared with AD group in our results. This gene encodes a member of calcium-dependent phospholipid-binding protein family playing a role in the regulation of cellular growth and in signal transduction pathways. Reduced ANXA2 expression is associated with osteosarcoma metastases. 27 Reports suggest that ANXA2 and, likely, ANXA1 may be endogenous suppressors of prostate cancer cell migration. 28 Thus, reduced or lost expression of ANXA2 may contribute to AI prostate cancer development and progression.
We also found genes related to apoptosis and proliferation and differentially expressed in AI compared with AD (P-valueo0.01), which are first reported in prostate cancer (Table 1) . Overexpression of human EMP-1 gene can inhibit the proliferation of cell with S-phase arrested and G1-phase prolonged. EMP-1 may be one of the regulators involved in cell signaling, cell communication and adhesion regulation. 29 Thioredoxin domain containing 5 is one member of the protein disulfide isomerase family, highly expressed in endothelial cells, and protects endothelial cells from apoptosis under hypoxia. 30 Tumor necrosis factor receptor superfamily member 10a (TNFRSF10A) is highly expressed in metastatic gastric carcinoma and tumor-infiltrating lymphocytes. 31 TNFRSF10A is activated in drug-sensitive cells in response to anticancer drugs depending on the cytotoxic effect of each drug. 32 Ribosomal protein S19 (RPS19) encodes a ribosomal protein that is a component of the 40S subunit. The protein belongs to the S19E family of ribosomal proteins and is located in the cytoplasm. Study suggests that RPS19 overexpression might be a universal signal of rapid cell growth in tissues. 33 All the above-mentioned genes are first reported in prostate cancer in this study, wherein their role in AI progression is plausible and yet to be proved by further research.
The progression of prostate cancer is closely related to hormone regulation disorder. We found in our study a group of genes significantly differentially expressed in AI in comparison with AD, which play a role in hormone regulation and other important biological processes, such as proliferation, motility and synthesis (Figure 3) . Androgen-independent prostate cancer Q Wei et al P53 regulates human glycoprotein hormone and human growth hormone. 34, 35 Breast cancer 1 (BRCA1) encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability and acts as a tumor suppressor. The loss of the androgen receptor expression, together with the observed loss of other steroid hormone receptors in BRCA1-mutated tumors, may lead to a hormone-independent growth or to antihormone-resistant growth of these tumors. 36 The CDK2-BRCA1-Nucleophosmin pathway coordinately functions in cell growth and tumor progression pathways.
37 BRCA1 can also stimulate Janus kinase 2 (JAK2)'s expression. 38 As a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways, JAK2 (a protein tyrosine kinase), has been found to be constitutively associated with the prolactin receptor and is required for responses to gamma interferon. It is a novel pathway in angiotensin II-dependent activation of steroidogenic acute regulatory protein (StAR) expression and steroidogenesis in adrenocortical cells and is required for ongoing protein synthesis in angiotensin II-mediated StAR transcription.
39 JAK2 phosphorylation is suppressed by estrogen, which inhibits growth hormone signaling. 40 Although the prostate is considered the prototype AD gland, there is increasing evidence that estrogens also profoundly affect its growth, differentiation and maintenance. 4 A large number of studies have shown both inhibitory and stimulatory effects of estrogens on prostatic growth. 41, 42 In hormone refractory prostate cancer, estrogens may have a role as an alternative mitogenic pathway and as such may represent a possible target for therapeutic intervention when the tumor progresses from an AD to an AI proliferation stage. 5 They were also deleted in malignant brain tumors 1 (DMBT1) in this study, besides JAK2, which was differentially expressed in AI compared with AD and related to estrogen. DMBT1 is lost from human chromosome 10q associated with the progression of human cancers. The gene DMBT1 was originally isolated based on its deletion in a medulloblastoma cell line, and may not be a classical tumor supressor gene, but rather plays a role in the interaction of tumor cells and the immune system. a 'm' signifies upregulation; 'k' signifies downregulation. The number in the parentheses indicates the average log2 ratio of the AI compared with AD. b The P-value was calculated using all the data for each particular gene and comparing the AI and AD groups.
Androgen-independent prostate cancer Q Wei et al DMBT1 is also an estrogen-responsive gene with a possible role in endometrial proliferation or differentiation. 43 The redistribution and upregulation of DMBT1 in normal and hyperplastic tissues flanking malignant tumors, and its downregulation in carcinomas suggests a potential role in breast cancer. 44 DMBT1 is likely to play a differential role in the genesis of digestive tract carcinomas. 45 It may be involved in terminal differentiation of prostate and vas deferens, but there is no evidence implicating its role in prostatic carcinogenesis.
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CD40 is related to thyroid hormone, 47 and the loss of CD40 expression is associated with prostate cancer progression, and CD40 expression on gastric carcinoma may be associated with cell survival and elevation of cell motility. 48, 49 Endothelial CD40, through activation of the phosphoinositide-3-kinase (PI3K)/Akt signaling pathway, regulates cell survival, proliferation, migration and vessel-like structure formation, all processes considered to be critical for angiogenesis. 50 S100A6 regulates parathyroid hormone. 51 Observed differential expression of S100A6 and S100A4 suggests that S100A6, rather than S100A4, is associated with human colorectal adenocarcinoma tumorigenesis, invasion and metastasis. 52 Carboxypeptidase E is a key enzyme for pro-gonadotropin-releasing hormone processing 53 and is also involved in gut hormone processing. 54 Addition of follicle-stimulating hormone to Sertoli cells increased the MMP-14 mRNA level, implicating a role in spermatogenesis. 55 Genes of C3, hormone-sensitive lipase and peroxisome proliferative-activated receptor-gamma may exert a modifying effect on lipid and glucose metabolism in familial combined hyperlipidemia. 56 CASP6 is sufficient for full activation of melanin-concentrating hormone receptor 2. 57 All the genes discussed above are related to hormones and play important roles in the vital stages of the cell life cycle. Significantly, differentially expressed in AI compared with AD, they may function in important ways in the pathogenesis of prostate cancer and the transition from AD to AI and could be potential biomarkers.
Angiogenesis
Angiogenesis is essential for the growth and metastatic propagation of cancer. Increased microvessel formation is a feature of many cancers including prostate cancer where quantification of microvessel density correlates with disease stage and outcome. 6, 7, 8 Aberrant blood vessel formation is associated with anomalies in pathways involved in apoptosis, androgen receptor (AR) signaling, signal transduction, cytokine function and cellular adhesion. 58 In this study, there were two genes (CD40 and TIMP3) differentially expressed in AI compared with AD and associated with angiogenesis. CD40 was discussed above.
Tissue inhibitor of metalloproteinase 3 (TIMP3) nearly threefold lower change , expressed in AI compared with AD, belongs to the TIMP gene family. The proteins encoded by this gene family are natural inhibitors of the matrix metalloproteinases, a group of peptidases involved in degradation of the extracellular matrix, and have the ability to induce a Fas-associated death domaindependent type II apoptotic pathway to modulate extracellular matrix remodeling during embryonic development and disease and to inhibit vascular endothelial factor-mediated angiogenesis. 59 With the negative effect of transforming growth factor beta-1 on a disintegrin-like and metallopeptidse with thrombospondin (ADAMTS)-1, -5, -9, and -15 coupled with increases in their inhibitor, TIMP3 may aid the accumulation of versican in the stromal compartment of the prostate in benign prostatic hyperplasia and prostate cancer. 60 The expression of this gene is induced in response to mitogenic stimulation and subject to cell-cycle regulation. Reduced expression of TIMP3 protein in esophageal adenocarcinoma is associated with increased tumor invasiveness, and correlates with invasive activity and Androgen-independent prostate cancer Q Wei et al metastasis in esophageal squamous cell carcinoma. 61, 62 The dysregulation of these two genes may play a role in AI progression.
Conclusion
In this study, using cDNA microarrays with AI and AD patients' specimen, we identified several genes and subcategories of functionally associated genes that were differentially expressed in AI prostate cancer, some of which are first reported to AI prostate cancer. Although the full biological significance of the differentially expressed genes remains to be elucidated, they are promising candidates for further studies and functional analyses, which may lead to new insights into the molecular processes involved in the development of AI prostate cancer.
